Archives
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2018-07
-
br Estrogen receptors activate mGluR signaling pathways In o
2019-09-24
Estrogen receptors activate mGluR signaling pathways In order to distinguish the opposing effects of estradiol on CREB phosphorylation, we turned to a “bottom-up” approach, working backwards from CREB phosphorylation to pharmacologically isolate the two signaling pathways (Boulware et al., 2005).
-
In humans the ER is
2019-09-24
In humans, the ERα is encoded by the gene ESR1, located on chromosome 6, locus 6q25.1 (Gosden, Middleton, & Rout, 1986). In addition to the full-length ERα isoform (66kDa), several shorter isoforms (36kDa, 46kDa) have been identified as a result of the presence of alternate start codons, or as produ
-
br Methods br Discussion and
2019-09-24
Methods Discussion and conclusions There were no statistically significant differences in pulmonary function outcomes (FEV1 and FVC) between the placebo and BAY 85-8501 treatment groups. The decline in mean FEV1 from baseline to EOT in the placebo group was attributed statistically to a few pa
-
It is particularly notable that CYP
2019-09-24
It is particularly notable that CYP2D6 appears to be the most stable of the major CYP450 kras-pdeδ pathway in its expression over time in vitro and appears to be least affected by culture conditions and sample to sample variability (i.e., CYP2D6 expression is remarkably consistent over time and bet
-
CXCR is not only critical in the B cell lineage
2019-09-24
CXCR5 is not only critical in the B cell lineage in FL. A high proportion of CXCR5-expressing follicular helper T cells (TFH) were observed in FL but not in closely related DLBCL [141] and further investigation revealed that FL regulatory T cells (Tregs) used a CXCL13-CXCR5 autocrine loop for positi
-
CXCR is not only critical in the B cell lineage
2019-09-24
CXCR5 is not only critical in the B cell lineage in FL. A high proportion of CXCR5-expressing follicular helper T cells (TFH) were observed in FL but not in closely related DLBCL [141] and further investigation revealed that FL regulatory T cells (Tregs) used a CXCL13-CXCR5 autocrine loop for positi
-
br Are incretins the only mediators of the anti hyperglycaem
2019-09-24
Are incretins the only mediators of the anti-hyperglycaemic effects of DPP-4 inhibitors? Even though both GLP-1 and GIP were identified as substrates for DPP-4 early on [17], [19], [20], [22], and DPP-4 inhibition in vivo raises levels of the intact endogenous forms of both of them [43], [44], fr
-
Boulares group has demonstrated that the NF
2019-09-24
Boulares group [82] has demonstrated that the NF-κB1/p50 NF-κB, a family member of type I NF-κB, is an excellent substrate for DNA-PK, which-dependent phosphorylation of NF-κB1 at serine 20 appears to enhance its binding to DNA as either a homodimer or a heterodimer with p65 NF-κB and the ability of
-
Ligand independent constitutively active variants have also
2019-09-24
Ligand-independent, constitutively active variants have also been found in receptors with associated tyrosine kinases. In approximately 60% of patients harboring inflammatory hepatocellular adenomas (IHCAs), these adenomas have been caused by small in-frame deletions in the cytokine-binding domain
-
br Conflicts of interest br Introduction Arylamine N acetylt
2019-09-23
Conflicts of interest Introduction Arylamine N-acetyltransferase 1 (NAT1, EC 2.3.1.5) is a cytosolic enzyme that catalyses the acetylation of small molecule arylamines, hydrazines and sulphonamides (Hein, 2002). Found in most BTL-104 in the body, NAT1 expression is regulated at the transcript
-
br Materials and methods br Results The BUN
2019-09-23
Materials and methods Results The BUN and creatinine levels in the saline-treated CRF group were found to be significantly higher than those in the sham-operated control rats treated with either montelukast or saline (p suppressed the LDH activity (pAsiatic acid pathway tissues, were found to
-
The secondary objective of the present study was
2019-09-23
The secondary objective of the present study was to evaluate the pharmacokinetics, safety, and tolerability of multiple oral doses of 450-mg delafloxacin to reach steady state in healthy male and female subjects. After multiple dosing of oral delafloxacin, steady state was reached after 4 days of do
-
Previously the N glycan in V of HXB HXB LAI
2019-09-23
Previously, the N-glycan in V3 of HXB2, HXB10, LAI and BRU strains was reported to be dispensable for their infectivity to T cell lines, although detailed growth kinetics and experimental conditions were not described 4, 5, 6, 7, 8. The experiments appear to have been done by infection initiated wit
-
Recent studies investigating the effects of
2019-09-23
Recent studies investigating the effects of mesenchymal stem cell (MSC) therapy in rodent models including chronic renal failure and glomerulonephritis have demonstrated that MSC therapy can result in beneficial effects [57], [58]. In cats, autologous intra-renal injections of either adipose tissue-
-
The data presented above clearly indicate an
2019-09-23
The data presented above clearly indicate an important role of eIF4E for the nucleocytoplasmic transport of the human iNOS mRNA. To analyze the sequence elements of the iNOS mRNA that are important for this eIF4E-mediated transport we performed transient transfection experiments using constructs con
14983 records 971/999 page Previous Next First page 上5页 971972973974975 下5页 Last page